Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]

It was developed by Inhibitex.[3]

See also

  • MSCRAMM (microbial surface components recognizing adhesive matrix molecules)

References

  1. ^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
  2. ^ Pan A, Lorenzotti S, Zoncada A (January 2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-Infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
  3. ^ John JF (October 2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Current Opinion in Molecular Therapeutics. 8 (5): 455–60. PMID 17078388.
Allikas: https://en.wikipedia.org/wiki/Tefibazumab
No tags for this post.